Navigation Links
ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:12/31/2008

EXTON, Pa., Dec. 31 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 27th Annual J.P. Morgan Healthcare Conference at 5:30 P.M. ET (2:30 P.M. PT) on Wednesday, January 14, 2009. The conference is being held at the Westin St. Francis Hotel in San Francisco.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma Provides Update on Vancocin(R)
2. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
3. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
4. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
5. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
6. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
7. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
8. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
9. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Augments Senior Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2016)... ... December 11, 2016 , ... It’s hard for an inventor from ... Tired of the sneezing, watery eyes and general discomfort associated with allergic reactions, he ... then created a prototype of the patent-pending CLEAN AIR NOSE FILTER, an accessory that ...
(Date:12/11/2016)... ... December 11, 2016 , ... A brand new organic skincare ... introduced 16 new products to it's existing line. "We started with a simple ... to supply more products to our customers that would provide safe and effective ...
(Date:12/11/2016)... ... 11, 2016 , ... The 31st annual iaedp (International Association ... online. This year’s conference event will continue the Symposium’s reputation for presenting the ... take place March 22 - 26 at the Green Valley Resort and Spa ...
(Date:12/10/2016)... ... December 09, 2016 , ... Even with breast cancer ... greatly in recent years. This can be attributed to the improvement in breast ... equally distributed. In response, Mediaplanet’s latest, cross-platform edition of “Breast Cancer Care” spotlights ...
(Date:12/10/2016)... ... December 10, 2016 , ... Holiday shopping, ... all sources of external stimuli that can put a great deal of stress ... spread holiday cheer through gifts, food and festive gatherings can lead to excessive ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 2016  Nevro Corp. (NYSE: NVRO ), ... evidence-based solutions for the treatment of chronic pain, today ... has filed a lawsuit for patent infringement.  The lawsuit, ... District of Delaware , alleges that ... to stimulation leads, batteries, and telemetry units. ...
(Date:12/9/2016)... -- MSD, a nationally recognized supplier of technology enabled ... health care facilities, announced today that it has completed ... a privately held national distributor of medical supplies and ... segments. We would like to welcome First Choice to ... will deliver significant and immediate value to MSD,s customers ...
(Date:12/9/2016)... -- External Defibrillators, Implantable Cardioverter Defibrillators, ... Cardiac Resynchronization Therapy Defibrillators (CRT-D), Manual External Defibrillators, ... The global defibrillators market is expected ... 2016-2020 and CAGR of 5.1% from 2020-2026. The ... of 5.2% from 2016 to 2026. The market ...
Breaking Medicine Technology: